myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity
Clicks: 143
ID: 214605
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
130 views
22 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
It has been suggested that myeloid neoplasms with isolated isochromosome 17q[MN i(17q)] comprise a distinct entity with poor prognosis. However, literature reports show a considerable clinical and molecular heterogeneity. We describe a 58-year-old male patient who was diagnosed as refractory anemia with multilineage dysplasia and ringed sideroblasts with isolated i(17q). Though he initially responded well to erythropoietin, he gradually progressed to an aggressive form of MDS/MPN refractory to azacytidine and died 29 months after first diagnosis. Notably, in contrast to disease advancement, his karyotype reverted to normal, whereas his mutational profile remained unchanged. To our knowledge this is the first report of karyotype normalization during disease progression in patients with MN i(17q), suggesting that the i(17q) anomaly is dispensable for the leukemic transformation and highlighting the underlying clinical and molecular complexity which both have to be resolved before the establishment of MN with isolated i(17q) as a distinct entity.
| Reference Key |
lamprianidou2017mediterraneanmyeloid
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Eleftheria Lamprianidou;Chryssoula Kordella;Menelaos Papoutselis;Zoi Bezyrgiannidou;Evangelia Nakou;Spyros Papamichos;Emmanouil Spanoudakis;Andreas Giannopoulos;Katerina Zoi;Ioannis Kotsianidis |
| Journal | aktualʹnì pitannâ farmacevtičnoï ì medičnoï nauki ta praktiki |
| Year | 2017 |
| DOI |
10.4084/mjhid.2017.066
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.